CA2946597C - Method of treating advanced non-alcoholic steatohepatitis - Google Patents

Method of treating advanced non-alcoholic steatohepatitis Download PDF

Info

Publication number
CA2946597C
CA2946597C CA2946597A CA2946597A CA2946597C CA 2946597 C CA2946597 C CA 2946597C CA 2946597 A CA2946597 A CA 2946597A CA 2946597 A CA2946597 A CA 2946597A CA 2946597 C CA2946597 C CA 2946597C
Authority
CA
Canada
Prior art keywords
compound
patient
formulated
nash
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2946597A
Other languages
English (en)
French (fr)
Other versions
CA2946597A1 (en
Inventor
Kazuko Matsuda
Yuichi Iwaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Priority to CA3205812A priority Critical patent/CA3205812A1/en
Publication of CA2946597A1 publication Critical patent/CA2946597A1/en
Application granted granted Critical
Publication of CA2946597C publication Critical patent/CA2946597C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Alcoholic Beverages (AREA)
CA2946597A 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis Active CA2946597C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3205812A CA3205812A1 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461990606P 2014-05-08 2014-05-08
US61/990,606 2014-05-08
US201462042072P 2014-08-26 2014-08-26
US62/042,072 2014-08-26
US14/490,618 US9346754B2 (en) 2014-05-08 2014-09-18 Method of treating advanced non-alcoholic steatohepatitis
US14/490,618 2014-09-18
PCT/US2015/029457 WO2015171755A2 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3205812A Division CA3205812A1 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Publications (2)

Publication Number Publication Date
CA2946597A1 CA2946597A1 (en) 2015-11-12
CA2946597C true CA2946597C (en) 2023-09-12

Family

ID=54367221

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3205812A Pending CA3205812A1 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis
CA2946597A Active CA2946597C (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3205812A Pending CA3205812A1 (en) 2014-05-08 2015-05-06 Method of treating advanced non-alcoholic steatohepatitis

Country Status (10)

Country Link
US (1) US9346754B2 (OSRAM)
EP (1) EP3139911B1 (OSRAM)
JP (1) JP6672173B2 (OSRAM)
KR (1) KR102386018B1 (OSRAM)
CN (1) CN106456576A (OSRAM)
BR (1) BR112016025369A2 (OSRAM)
CA (2) CA3205812A1 (OSRAM)
ES (1) ES2964286T3 (OSRAM)
TW (1) TW201622716A (OSRAM)
WO (1) WO2015171755A2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457306B2 (en) * 2014-10-07 2016-10-04 Life Technologies Corporation Regulated vacuum off-gassing of gas filter for fluid processing system and related methods
JP2024522030A (ja) * 2021-05-28 2024-06-10 メディシノバ・インコーポレイテッド フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
WO2005105073A1 (en) * 2004-04-27 2005-11-10 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JP2013056834A (ja) * 2011-09-07 2013-03-28 Okayama Univ 線維化疾患治療剤
US8835499B2 (en) * 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Also Published As

Publication number Publication date
EP3139911A2 (en) 2017-03-15
KR102386018B1 (ko) 2022-04-14
CN106456576A (zh) 2017-02-22
EP3139911B1 (en) 2023-10-25
WO2015171755A2 (en) 2015-11-12
US20150322004A1 (en) 2015-11-12
BR112016025369A2 (pt) 2017-08-15
EP3139911A4 (en) 2017-12-20
TW201622716A (zh) 2016-07-01
ES2964286T3 (es) 2024-04-05
US9346754B2 (en) 2016-05-24
CA2946597A1 (en) 2015-11-12
KR20170003581A (ko) 2017-01-09
CA3205812A1 (en) 2015-11-12
JP2017518967A (ja) 2017-07-13
JP6672173B2 (ja) 2020-03-25

Similar Documents

Publication Publication Date Title
JP2019218379A (ja) 肝障害の治療方法
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
CA2946597C (en) Method of treating advanced non-alcoholic steatohepatitis
WO2018079149A1 (ja) 白内障の予防剤、治療剤、およびこれらを製造するためのｈａｔ阻害剤の使用
US9498458B2 (en) Method of inhibiting or treating fibrosis
KR102352728B1 (ko) 트리글리세라이드, 총 콜레스테롤, 및 저밀도 지단백질의 혈중농도를 감소시키는 방법
ES2792850T3 (es) Método para tratar la fibrosis pulmonar idiopática
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421

EEER Examination request

Effective date: 20200421